[go: up one dir, main page]

WO2004039322A3 - Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal - Google Patents

Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal Download PDF

Info

Publication number
WO2004039322A3
WO2004039322A3 PCT/US2003/033730 US0333730W WO2004039322A3 WO 2004039322 A3 WO2004039322 A3 WO 2004039322A3 US 0333730 W US0333730 W US 0333730W WO 2004039322 A3 WO2004039322 A3 WO 2004039322A3
Authority
WO
WIPO (PCT)
Prior art keywords
blockade
schizophrenia
reuptake
prefrontal
adjunctive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/033730
Other languages
English (en)
Other versions
WO2004039322A2 (fr
Inventor
Graham V Williams
Stacy A Castner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIICRO Inc
Original Assignee
MIICRO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIICRO Inc filed Critical MIICRO Inc
Priority to AU2003284899A priority Critical patent/AU2003284899A1/en
Publication of WO2004039322A2 publication Critical patent/WO2004039322A2/fr
Publication of WO2004039322A3 publication Critical patent/WO2004039322A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des polythérapies pour le traitement d'un ou de plusieurs troubles et/ou maladies médicales. L'invention concerne également des procédures associées. Un aspect de l'invention concerne un polythérapie pour des patients et/ou pour des sujets diagnostiqués comme souffrant de schizophrénie. Cette thérapie comprend une combinaison optimale d'un médicament bloquant les récepteurs 5-HT-2A, d'un médicament bloquant des récepteurs D2, et d'un médicament bloquant le recaptage de la dopamine.
PCT/US2003/033730 2002-10-29 2003-10-24 Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal Ceased WO2004039322A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003284899A AU2003284899A1 (en) 2002-10-29 2003-10-24 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42198002P 2002-10-29 2002-10-29
US60/421,980 2002-10-29

Publications (2)

Publication Number Publication Date
WO2004039322A2 WO2004039322A2 (fr) 2004-05-13
WO2004039322A3 true WO2004039322A3 (fr) 2004-10-07

Family

ID=32230298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033730 Ceased WO2004039322A2 (fr) 2002-10-29 2003-10-24 Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal

Country Status (2)

Country Link
AU (1) AU2003284899A1 (fr)
WO (1) WO2004039322A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211289B2 (en) 2003-01-16 2015-12-15 Acadia Pharmaceuticals Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US9296694B2 (en) 2000-03-06 2016-03-29 Acadia Pharmaceuticals Inc. Azacyclic compounds

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
AU2003247615B2 (en) 2002-06-24 2007-08-09 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
RU2417986C2 (ru) 2004-09-27 2011-05-10 Акадиа Фармасьютикалз Инк. Синтез n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n'-(4-(2-метилпропилокси)фенилметил)карбамида, а также его тартрата и кристаллических форм
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
US20090306092A1 (en) * 2008-05-07 2009-12-10 H. Lundbeck A/S Method for treating cognitive deficits
WO2017015272A1 (fr) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Procédés de préparation de n-(4-fluorobenzyl)-n-(1-méthylpipéridin-4-yl)-n'-(4-2-méthylpropyloxy)phénylméthyl)carbamide, son sel de tartrate et sa forme polymorphe c
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558311A1 (fr) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer
CA3047354A1 (fr) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique contenant de l'asenapine et un polysiloxane ou un polyisobutylene
WO2018200977A1 (fr) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
WO2019046167A1 (fr) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. Formulations de pimavansérine
JP7502199B2 (ja) 2018-06-20 2024-06-18 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296694B2 (en) 2000-03-06 2016-03-29 Acadia Pharmaceuticals Inc. Azacyclic compounds
US9211289B2 (en) 2003-01-16 2015-12-15 Acadia Pharmaceuticals Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US9566271B2 (en) 2003-01-16 2017-02-14 Acadia Pharmaceuticals Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Also Published As

Publication number Publication date
AU2003284899A8 (en) 2004-05-25
WO2004039322A2 (fr) 2004-05-13
AU2003284899A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2004039322A3 (fr) Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal
WO2006064453A3 (fr) Agents de ciblage pour une imagerie moleculaire
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
EP1558220A4 (fr) Compositions orales pour le traitement de maladies
WO2005020972A3 (fr) Polytherapie pour le traitement de troubles neovasculaires oculaires
WO2006064451A3 (fr) Agents de contraste de ciblage ou agents therapeutiques de ciblage destines a une imagerie et a une therapie moleculaires
WO2002058564A3 (fr) Articles chirurgicaux
WO2002095352A3 (fr) Systeme de surveillance de l'observance d'un traitement
WO2003009815A3 (fr) Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
WO2004041067A3 (fr) Prevention et traitement d'une maladie synucleopathique
EP1586338A3 (fr) Utilisation d'antioxydants pour la prévention d'oxydation et la réduction de la dégradation des principes actifs dans les articles médicaux libérant des principes actifs
WO2002098890A3 (fr) Mark utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2004043341A3 (fr) Traitement pour choc hémorragique
GB2409169B (en) Drug nebulizer usable with a diagnostic or therapeutic instrument, such as a bronchoscope
WO2004039321A8 (fr) Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2007039123A3 (fr) Traitement combine
UA83018C2 (uk) Комбінація рофлуміласту і формотеролу для лікування захворювань дихальних шляхів
GB2370507B (en) Apparatus for the diagnosis and therapy of neuro-muscular and other tissue disorders
WO2002062300A3 (fr) Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs
NO20042586L (no) Behandlingsfremgangsmate
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP